RE:RE:RE:RE:RE:Andrey Omelchak - BNN - TOP PICKI think Goodman would have a lot of influence in an acquisition type of situation even if he does not control the vote directly. Anything can happen though! But I do believe a low multiple bid is very unlikely to succeed in this situation.
Especially for the shareholders who have been with the company for a longer period of time, the investment case was largely based on the management's ability to execute. Now, I would argue the investment case includes a platform in the Americas (ex-USA) that's hard to find elsewhere. It takes a lot of time to build one. And in the pharma business, time
really is money.
In addition, for the investment case, there's of course the cash flow, the pipeline (combined with the existing platform = widening margins), the net cash/financial assets, etc.
So, in the end, I believe for many GUD investors, they will pay close attention to what Goodman and the management think. Unsurprisingly, here's Armoyan:
“I really like the leaders. This is one of the best teams of managers I have ever met. I’m convinced they’re going to make me money,” George Armoyan said over the phone, referring to Jonathan Goodman and Knight CEO Samira Sakhia.
Regarding the dividend, I doubt there will be one until this thing is acquired. They're not done growing and investing. They're also not going to do anything just to look good, whether's it's paying a dividend, in-licensing products or doing M&A with unfavorable terms, straying from the strategy and principles, etc.